Fundraising Fox

Eclipse Bio

San Diego, US · Founded 2017 · Delaware corporation · 42 employees on LinkedIn · 4 known investors

Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.

Founders & leadership

Eclipse Bio was founded in 2017 by Eugene Yeo.

EY
Eugene YeoFounder
PC
Peter ChuExecutive
EL
Eric L Van NostrandNamed on SEC filing
HK
Hallie KuhnNamed on SEC filing

Board

EWEdmond Wong
Edmond WonginBoard MemberPartner at iGlobe Partners
DV
Daniel VasellaBoard director

Investors · 4

Reported raises · per SEC filings

Form D private placements

$16.9M disclosed across 2 rounds · 2021–2025

$4.9MraisedNov 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter ChuExecutive Officer, Director
  • Daniel VasellaDirector
  • Edmond WongDirector
  • Eugene YeoDirector
Offering amount
$7.2M
Amount sold
$4.9M
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$12MraisedSep 2021 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel VasellaDirector
  • Peter ChuExecutive Officer, Director
  • Eric L Van NostrandDirector
  • Hallie KuhnDirector
  • Eugene W YeoDirector
Offering amount
$15M
Amount sold
$12M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Companies competing with Eclipse Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$349.8K
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$1.6M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Eclipse Bio do?
Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.
Who founded Eclipse Bio?
Eclipse Bio was founded by Eugene Yeo in 2017.
Who are Eclipse Bio's investors?
Eclipse Bio's investors include Brainstorm Ventures, iGlobe Partners, Magnetic Ventures, Phoenix Venture Partners.
How much funding has Eclipse Bio raised?
Eclipse Bio has disclosed $16.9M raised across 2 rounds.
Where is Eclipse Bio headquartered?
Eclipse Bio is headquartered in San Diego, US.